Status:
COMPLETED
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia
Lead Sponsor:
Vastra Gotaland Region
Collaborating Sponsors:
The Canadian Blood and Marrow Transplant Group
Australasian Leukaemia and Lymphoma Group
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
51-70 years
Phase:
NA
Brief Summary
This study compares overall survival between patients with acute myeloid leukemia, who are in complete remission following initial treatment with chemotherapy and whose remission is maintained either ...
Detailed Description
Objectives: The primary objective of this study is to determine whether RICT leads to an improved overall survival compared to conventional treatment for AML. The secondary objectives of this study ...
Eligibility Criteria
Inclusion
- Newly diagnosed patients with de novo or secondary AML
- Intermediate or poor risk
- In first complete remission
- Age 51-70 years
- Fit for the procedure
- Fit for further consolidation chemotherapy
Exclusion
- Planned for a full-dose allogeneic transplant
Key Trial Info
Start Date :
December 18 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2018
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT00342316
Start Date
December 18 2003
End Date
July 20 2018
Last Update
January 27 2020
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
2
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
3
Austalasian Leukaemia &Lymphoma Group Limited
East Melbourne, Victoria, Australia, 3002
4
Cancer Care Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9